Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Microbes can help explain the evolution of host altruism.

Lewin-Epstein O, Aharonov R, Hadany L.

Nat Commun. 2017 Jan 12;8:14040. doi: 10.1038/ncomms14040.

2.

Identifying and Investigating Unexpected Response to Treatment: A Diabetes Case Study.

Ozery-Flato M, Ein-Dor L, Parush-Shear-Yashuv N, Aharonov R, Neuvirth H, Kohn MS, Hu J.

Big Data. 2016 Sep;4(3):148-59. doi: 10.1089/big.2016.0017. Epub 2016 Aug 19.

PMID:
27541627
3.

Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.

Cohen KA, El-Hay T, Wyres KL, Weissbrod O, Munsamy V, Yanover C, Aharonov R, Shaham O, Conway TC, Goldschmidt Y, Bishai WR, Pym AS.

EBioMedicine. 2016 Jul;9:170-179. doi: 10.1016/j.ebiom.2016.05.041. Epub 2016 Jun 1.

4.

Changing the approach to treatment choice in epilepsy using big data.

Devinsky O, Dilley C, Ozery-Flato M, Aharonov R, Goldschmidt Y, Rosen-Zvi M, Clark C, Fritz P.

Epilepsy Behav. 2016 Mar;56:32-7. doi: 10.1016/j.yebeh.2015.12.039. Epub 2016 Jan 29.

5.

A system for identifying and investigating unexpected response to treatment.

Ozery-Flato M, Ein-Dor L, Neuvirth H, Parush N, Kohn MS, Hu J, Aharonov R.

AMIA Jt Summits Transl Sci Proc. 2015 Mar 25;2015:137-41. eCollection 2015.

6.

Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary.

Pentheroudakis G, Pavlidis N, Fountzilas G, Krikelis D, Goussia A, Stoyianni A, Sanden M, St Cyr B, Yerushalmi N, Benjamin H, Meiri E, Chajut A, Rosenwald S, Aharonov R, Spector Y.

Mol Cancer. 2013 Jun 10;12:57. doi: 10.1186/1476-4598-12-57.

7.

Predicting progression of bladder urothelial carcinoma using microRNA expression.

Rosenberg E, Baniel J, Spector Y, Faerman A, Meiri E, Aharonov R, Margel D, Goren Y, Nativ O.

BJU Int. 2013 Nov;112(7):1027-34. doi: 10.1111/j.1464-410X.2012.11748.x. Epub 2013 Feb 6.

8.

Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.

Pentheroudakis G, Spector Y, Krikelis D, Kotoula V, Meiri E, Malamou-Mitsi V, Fountzilas G, Sanden M, Pavlidis N, Benjamin H, Aharonov R.

Clin Exp Metastasis. 2013 Apr;30(4):431-9. doi: 10.1007/s10585-012-9548-3. Epub 2012 Nov 4.

PMID:
23124598
9.

Classification of the four main types of lung cancer using a microRNA-based diagnostic assay.

Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky I, Edmonston TB, Bibbo M, Thurm C, Horowitz L, Huang Y, Feinmesser M, Hou JS, St Cyr B, Burnstein I, Gibori H, Dromi N, Sanden M, Kushnir M, Aharonov R.

J Mol Diagn. 2012 Sep;14(5):510-7. doi: 10.1016/j.jmoldx.2012.03.004. Epub 2012 Jun 27.

10.

A second-generation microRNA-based assay for diagnosing tumor tissue origin.

Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser M, Huszar M, Fogt F, Ashkenazi K, Sanden M, Goren E, Dromi N, Zion O, Burnstein I, Chajut A, Spector Y, Aharonov R.

Oncologist. 2012;17(6):801-12. doi: 10.1634/theoncologist.2011-0466. Epub 2012 May 22.

11.

Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer.

Weissmann-Brenner A, Kushnir M, Lithwick Yanai G, Aharonov R, Gibori H, Purim O, Kundel Y, Morgenstern S, Halperin M, Niv Y, Brenner B.

Int J Oncol. 2012 Jun;40(6):2097-103. doi: 10.3892/ijo.2012.1403. Epub 2012 Mar 16.

PMID:
22426940
12.

Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.

Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN.

Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599. Epub 2011 Apr 29.

13.

Accurate classification of metastatic brain tumors using a novel microRNA-based test.

Mueller WC, Spector Y, Edmonston TB, St Cyr B, Jaeger D, Lass U, Aharonov R, Rosenwald S, Chajut A.

Oncologist. 2011;16(2):165-74. doi: 10.1634/theoncologist.2010-0305. Epub 2011 Jan 27.

14.

A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.

Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, Ashkenazi K, Goren E, Meiri E, Morgenstern S, Perelman M, Barshack I, Goren Y, Edmonston TB, Chajut A, Aharonov R, Bentwich Z, Rosenfeld N, Cohen D.

J Mol Diagn. 2010 Nov;12(6):771-9. doi: 10.2353/jmoldx.2010.090169. Epub 2010 Sep 23.

15.

Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin.

Rosenwald S, Gilad S, Benjamin S, Lebanony D, Dromi N, Faerman A, Benjamin H, Tamir R, Ezagouri M, Goren E, Barshack I, Nass D, Tobar A, Feinmesser M, Rosenfeld N, Leizerman I, Ashkenazi K, Spector Y, Chajut A, Aharonov R.

Mod Pathol. 2010 Jun;23(6):814-23. doi: 10.1038/modpathol.2010.57. Epub 2010 Mar 26.

16.

hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, Aharonov R.

Cancer Res. 2010 Mar 1;70(5):1916-24. doi: 10.1158/0008-5472.CAN-09-3993. Epub 2010 Feb 16.

17.

Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M.

J Clin Oncol. 2009 Apr 20;27(12):2030-7. doi: 10.1200/JCO.2008.19.4134. Epub 2009 Mar 9.

PMID:
19273703
18.

MicroRNAs accurately identify cancer tissue origin.

Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z, Cohen D, Chajut A, Barshack I.

Nat Biotechnol. 2008 Apr;26(4):462-9. doi: 10.1038/nbt1392. Epub 2008 Mar 23.

PMID:
18362881
19.

Identification of hundreds of conserved and nonconserved human microRNAs.

Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E, Spector Y, Bentwich Z.

Nat Genet. 2005 Jul;37(7):766-70. Epub 2005 Jun 19.

PMID:
15965474
20.

Dynamic model of the octopus arm. I. Biomechanics of the octopus reaching movement.

Yekutieli Y, Sagiv-Zohar R, Aharonov R, Engel Y, Hochner B, Flash T.

J Neurophysiol. 2005 Aug;94(2):1443-58. Epub 2005 Apr 13.

21.

MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues.

Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I, Einav U, Gilad S, Hurban P, Karov Y, Lobenhofer EK, Sharon E, Shiboleth YM, Shtutman M, Bentwich Z, Einat P.

Genome Res. 2004 Dec;14(12):2486-94.

22.

Learning input correlations through nonlinear temporally asymmetric Hebbian plasticity.

Gütig R, Aharonov R, Rotter S, Sompolinsky H.

J Neurosci. 2003 May 1;23(9):3697-714.

23.

High-dimensional analysis of evolutionary autonomous agents.

Segev L, Aharonov R, Meilijson I, Ruppin E.

Artif Life. 2003 Winter;9(1):1-20.

PMID:
12725679
24.

Localization of function via lesion analysis.

Aharonov R, Segev L, Meilijson I, Ruppin E.

Neural Comput. 2003 Apr;15(4):885-913.

PMID:
12689391

Supplemental Content

Loading ...
Support Center